nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

01.02.2012 | Inflammatory Disorders

B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis

verfasst von: Waka Ishida, Ken Fukuda, Mina Kajisako, Tamaki Sumi, Hironori Matsuda, Hideo Yagita, Atsuki Fukushima

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the roles that B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM) play in the development of antigen-induced experimental conjunctivitis (EC).

Methods

BALB/c mice were immunized with ragweed (RW) in alum. Ten days later, the mice were challenged with RW in eye drops. After 24 hours, the conjunctivas, blood and spleens were collected for histological analysis, measurement of serum immunoglobulin (Ig) levels, and both flow cytometric analysis and cytokine assays, respectively. The mice were injected intraperitoneally with anti-BTLA antibody, anti-HVEM antibody or control antibody during either induction phase or effector phase.

Results

Induction-phase treatment with anti-BTLA antibody but not anti-HVEM antibody significantly increased conjunctival eosinophil infiltration. Treatment with either antibody during the effector phase did not affect conjunctival eosinophil infiltration. Anti-BTLA antibody treatment during the induction phase reduced the B cell compartment and increased the CD11b-positive cell compartment in splenocytes. Additionally, anti-BTLA treatment upregulated IL-4 and IL-10 production of splenocytes stimulated by RW.

Conclusions

BTLA regulated the development of EC possibly by downregulating Th2 cytokine production and adjusting the compartments of immunocompetent cells. The regulation of EC by BTLA may be mediated by BTLA ligands other than HVEM.

Nur mit Berechtigung zugänglich

Trocme SD, Sra KK (2002) Spectrum of ocular allergy. Curr Opin Allergy Clin Immunol 2:423–427PubMedCrossRef

Keane-Myers A (2001) The pathogenesis of allergic conjunctivitis. Curr Allergy Asthma Rep 1:550–557PubMedCrossRef

Leonardi A, DeFranchis G, Zancanaro F, Crivellari G, De Paoli M, Plebani M, Secchi AG (1999) Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Investig Ophthalmol Vis Sci 40:3036–3040

Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Nanba K, Fukushima A, Fujishima H (2009) A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 25:365–372PubMedCrossRef

Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Hayashi K (2010) A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 26:165–174PubMedCrossRef

Ozaki A, Seki Y, Fukushima A, Kubo M (2005) The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model. J Immunol 175:5489–5497PubMed

Fukushima A, Yamaguchi T, Ishida W, Fukata K, Taniguchi T, Liu FT, Ueno H (2006) Genetic background determines susceptibility to experimental immune-mediated blepharoconjunctivitis: comparison of Balb/c and C57BL/6 mice. Exp Eye Res 82:210–218PubMedCrossRef

Fukagawa K, Nakajima T, Tsubota K, Shimmura S, Saito H, Hirai K (1999) Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J Allergy Clin Immunol 103:1220–1221PubMedCrossRef

Bonini S, Magrini L, Rotiroti G, Lambiase A, Tomassini M, Rumi C, Bonini S (1997) The eosinophil and the eye. Allergy 52:44–47PubMedCrossRef

10.

Fukushima A, Yamaguchi T, Ishida W, Fukata K, Yagita H, Ueno H (2006) Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40. Investig Ophthalmol Vis Sci 47:657–663CrossRef

11.

Fukushima A, Yamaguchi T, Ishida W, Fukata K, Mittler RS, Yagita H, Ueno H (2005) Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 175:4897–4903PubMed

12.

Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116–126PubMedCrossRef

13.

Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548PubMedCrossRef

14.

Murphy KM, Nelson CA, Sedý JR (2006) Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 6:671–681PubMedCrossRef

15.

Sumi T, Fukushima A, Fukuda K, Kumagai N, Nishida T, Yagita H, Ueno H (2007) Differential contributions of B7-1 and B7-2 to the development of murine experimental allergic conjunctivitis. Immunol Lett 108:62–67PubMedCrossRef

16.

Fukushima A, Yamaguchi T, Azuma M, Yagita H, Ueno H (2006) Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br J Ophthalmol 90:1040–1045PubMedCrossRef

17.

Tamachi T, Watanabe N, Oya Y, Kagami S, Hirose K, Saito Y, Iwamoto I, Nakajima H (2007) B and T lymphocyte attenuator inhibits antigen-induced eosinophil recruitment into the airways. Int Arch Allergy Immunol 143:50–55PubMedCrossRef

18.

Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM (2008) B and T lymphocyte attenuator regulates T cell survival in the lung. J Immunol 181:2973–2979PubMed

19.

Fukushima A, Yamaguchi T, Ishida W, Fukata K, Yagita H, Ueno H (2005) The interaction between ICOS and B7RP-1 is not required for the development of experimental murine allergic conjunctivitis. Biochem Biophys Res Commun 338:1726–1731PubMedCrossRef

20.

Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670–679PubMedCrossRef

21.

Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM (2005) B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells. J Immunol 174:3377–3385PubMed

22.

Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J (2004) An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 172:5931–5939PubMed

23.

Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM (2005) B and T lymphocyte attenuator regulates T-cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6:90–98PubMedCrossRef

24.

Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ (2008) CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 9:176–185PubMedCrossRef

25.

Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF ⁄ NGF receptor family. Cell 87:427–436PubMedCrossRef

26.

Hsu H, Solovyev I, Colombero A, Elliott R, Kelley M, Boyle WJ (1997) ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem 272:13471–13474PubMedCrossRef

27.

Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL (2005) A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 102:1116–1121PubMedCrossRef

28.

29.

Otsuki N, Kamimura Y, Hashiguchi M, Azuma M (2006) Expression and function of the B and T lymphocyte attenuator (BTLA ⁄ CD272) on human T cells. Biochem Biophys Res Commun 344:1121–1127PubMedCrossRef

30.

Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG (2009) Follicular helper T cells: lineage and location. Immunity 30:324–335PubMedCrossRef

31.

Kashiwakuma D, Suto A, Hiramatsu Y, Ikeda K, Takatori H, Suzuki K, Kagami S, Hirose K, Watanabe N, Iwamoto I, Nakajima H (2010) B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses. J Immunol 185:2730–2736PubMedCrossRef

32.

Xia L, Zhang S, Zhou J, Li Y (2010) A crucial role for B and T lymphocyte attenuator in preventing the development of CD4+ T cell-mediated herpetic stromal keratitis. Mol Vis 16:2071–2083PubMed

Titel: B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis
verfasst von: Waka Ishida
Ken Fukuda
Mina Kajisako
Tamaki Sumi
Hironori Matsuda
Hideo Yagita
Atsuki Fukushima
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 2/2012
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-011-1695-8

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Luminance-modulated adaptation in the global flash mfERG: a preliminary study of early retinal functional changes in high-risk glaucoma patients

Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis

Longterm cultures of the aged human RPE do not maintain epithelial morphology and high transepithelial resistance

Astigmatism and optical coherence tomography measurements

Microperimetry as a routine diagnostic test in the follow-up of retinal vein occlusion?

Analysis of causes of bullous keratopathy in East China: a 10-year retrospective study

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde